IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden · Delayed Price · Currency is SEK 1.788
+0.058 (3.35%)
Sep 23, 2026, 9:07 AM CET
IRLAB Therapeutics AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -53.84 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Depreciation & Amortization | 4.15 | 4.32 | 4.58 | 4.32 | 3.72 | 3.22 |
Other Amortization | - | - | - | - | 0.26 | 0.26 |
Asset Writedown & Restructuring Costs | - | - | - | - | 0.8 | - |
Other Operating Activities | -0.15 | 8.73 | 3.96 | - | - | 39.09 |
Change in Accounts Receivable | -14.76 | 5.68 | 2.79 | 3.63 | 3.63 | -12.81 |
Change in Other Net Operating Assets | -2.42 | 36.06 | 6.21 | 5.04 | -37.62 | 47.11 |
Operating Cash Flow | -67.02 | -55.22 | -65.59 | -164.85 | -142.61 | 128.64 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | -0.2 | -0.29 | -2.88 | -0.71 |
Sale (Purchase) of Intangibles | - | - | - | - | -0.5 | - |
Investing Cash Flow | - | - | -0.2 | -0.29 | -3.38 | -0.71 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 18.8 | 25 | 27.28 | - | - |
Long-Term Debt Repaid | - | -19.95 | -3.6 | -3.61 | -3.13 | -2.87 |
Lease Payments | -3.42 | -3.42 | -3.6 | -3.61 | -3.13 | -2.87 |
Net Debt Issued (Repaid) | -25.95 | -1.15 | 21.4 | 23.68 | -3.13 | -2.87 |
Issuance of Common Stock | 74.56 | 74.56 | - | - | - | - |
Other Financing Activities | -0 | -0 | - | - | - | -0.18 |
Financing Cash Flow | 48.61 | 73.41 | 21.4 | 23.68 | -3.13 | -3.05 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -1.02 | -3.24 | - | - | - | - |
Miscellaneous Cash Flow Adjustments | -0 | - | 0 | - | 0 | - |
Net Cash Flow | -19.43 | 14.94 | -44.39 | -141.47 | -149.12 | 124.89 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -67.02 | -55.22 | -65.79 | -165.14 | -145.49 | 127.93 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -84.47% | -96.10% | -69.52% | -2908.47% | -237.97% | 61.57% |
Free Cash Flow Per Share | -0.80 | -0.82 | -1.27 | -3.18 | -2.81 | 2.47 |
Levered Free Cash Flow | -123.15 | -18.3 | -38.77 | -99.98 | -103.57 | 69.69 |
Unlevered Free Cash Flow | -116.83 | -7.06 | -32.22 | -99.86 | -103.38 | 69.92 |
Free Cash Flow After Leases | -70.43 | -58.64 | -69.39 | -168.75 | -148.62 | 125.07 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 11.38 | 12.5 | 6.52 | 0.2 | 0.3 | 0.8 |
Change in Working Capital | -17.18 | 41.74 | 9 | 8.67 | -33.99 | 34.3 |